Research
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
The Brief
- Ziltivekimab, a monoclonal antibody, lowered inflammatory markers in the trial.
- It did not reduce cardiovascular events in patients with ASCVD and CKD.
Why it matters
The trial shows that lowering inflammatory markers with ziltivekimab did not translate into fewer cardiovascular events, which matters for research into inflammation as a treatment target in cardiovascular disease.
Who’s affected
- Patients with atherosclerotic cardiovascular disease and chronic kidney disease
(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...